Fig. 3: Anti-TACI L-H CAR shows superior efficacy in vivo against stress models of multiple myeloma.

a Schematic of MM1S curative model treated with 5e6 CAR+ cells intravenously 14 days after intravenous engraftment of 1e6 MM1S cells. b BLI imaging of a. c, Quantified BLI of a (5 mice per group +/– SEM, unpaired t test to Untransduced at day 35 where **=0.004935 for anti-TACI H-L, **=0.001696 for anti-TACI L-H, **=0.004928 for anti-BCMA). d Schematic of MM1S stress model treated with 2e6 CAR+ cells. e BLI imaging of d. f Quantified BLI of d (5 mice per group +/– SEM, experiment representative of 3 separate experiments each treated with a different ND, unpaired t test at day 28 between anti-TACI H-L and anti-TACI L-H where *=0.014174). g Schematic of RPMI-8226 subcutaneous model treated with 2e6 CAR+ cells intravenously 14 days after subcutaneous engraftment of 5e6 RPMI-8226 cells. h Survival of g (log-rank Mantel-Cox test **=0.0026). i Caliper measurements of individual mice from g for the first 50 days (5 mice per group, experiment representative of 2 separate experiments each treated with a different ND). Raw data is provided in the Source Data file. All tests were two-sided unless otherwise stated.